Search

Your search keyword '"EPIDERMAL growth factor receptors"' showing total 3 results
Start Over Descriptor "EPIDERMAL growth factor receptors" Publication Type Reviews
3 results on '"EPIDERMAL growth factor receptors"'

1. All Bruton's tyrosine kinase inhibitors have similar efficacy and risks: No.

Author

Rotstein, Dalia L

Subjects
*BRUTON tyrosine kinase, *PROTEIN-tyrosine kinase inhibitors, *EPIDERMAL growth factor receptors
Abstract

Bruton's tyrosine kinase inhibitors (BTKIs) are a novel class of molecules under investigation for treatment of multiple sclerosis (MS). As small molecules, they can cross the blood-brain barrier and affect microglia in the central nervous system (CNS), thus offering the promise of potentially treating neurodegenerative aspects of MS as well as inflammatory activity. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: A phase 2b, randomised, double-blind, placebo-controlled trial. [Extracted from the article]

Published
2022
Full Text
View/download PDF

2. Boehringer Ingelheim Support Services.

Subjects
*EPIDERMAL growth factor receptors
Abstract

The article reviews the Gilotrif Patient Services for cancer patients prescribed with Gilotrif (afatinib) oncology drugs from Boehringer Ingelheim.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results